EDN1 and colorectal cancer: Inhibiting YAP signaling restores sensitivity to oxaliplatin, suppresses proliferation, and enhances apoptosis, underscoring the therapeutic potential of targeting the EDN1-YAP axis to overcome chemoresistance in colorectal cancer.